

# europaean journal of gynaecological oncology

an International Journal

*Editors-in-Chief*

**A. Onnis**                      **P. Bószé**  
*Montréal (Canada)*              *Budapest (Hungary)*

*Associate Editor*

**M. Marchetti**  
*Padua (Italy)*

*Assistant Editor*

**J. Wilson**  
*San Diego - CA (USA)*

*Editorial Board*

H. H. Allen, <i>London, Ontario (Canada)</i>	A. F. Fuller Jr., <i>Boston, MA (USA)</i>	J. Menczer, <i>Savyon (Israel)</i>
S. O. Anteby, <i>Jerusalem (Israel)</i>	H. E. Geisler, <i>Indianapolis, IN (USA)</i>	J. Monsonego, <i>Paris (France)</i>
P. Audet-Lapointe, <i>Montreal (Canada)</i>	A. Gerbaulet, <i>Villejuif (France)</i>	B. Patsner, <i>New Jersey, NJ (USA)</i>
L. Aurelian, <i>Baltimore, MD (USA)</i>	A. Gorins, <i>Paris (France)</i>	A. Pinotti, <i>São Paulo (Brasil)</i>
A. Ayhan, <i>Ankara (Turkey)</i>	A.P.M. Heintz, <i>Utrecht (The Netherlands)</i>	S. M. Piver, <i>Buffalo, NY (USA)</i>
O. Balat, <i>Graziantep (Turkey)</i>	L. Ioannidou-Mouzaka, <i>Athens (Greece)</i>	S. Rakar, <i>Ljubljana (Slovenia)</i>
H. K. Barber, <i>New York, NY (USA)</i>	A. I. Karseladze, <i>Moscow (Russia)</i>	K. S. Raju, <i>London, England (UK)</i>
A. Basta, <i>Krakow (Poland)</i>	J. Klastersky, <i>Bruxelles (Belgium)</i>	J. H. Shepherd, <i>London, England (UK)</i>
H. C. Bender, <i>Dusseldorf (Germany)</i>	V. Kozachenko, <i>Moscow (Russia)</i>	P. Sismondi, <i>Turin (Italy)</i>
T. Charkviani, <i>Tbilisi (Georgia)</i>	B. Kralj, <i>Ljubljana (Slovenia)</i>	J. Stelmachów, <i>Warsaw (Poland)</i>
D. Dargent, <i>Lyon (France)</i>	E. Kubista, <i>Vienna (Austria)</i>	L. Ungár, <i>Budapest (Hungary)</i>
C. F. De Oliveira, <i>Coimbra (Portugal)</i>	A. P. Kudelka, <i>Houston, TX (USA)</i>	I. Vergote, <i>Leuven (Belgium)</i>
S. Dexeus Jr., <i>Barcelona (Spain)</i>	T. Maggino, <i>Padua (Italy)</i>	J. B. Vermorken, <i>Amsterdam (The Netherlands)</i>
G. De Palo, <i>Milan (Italy)</i>	J. Markowska, <i>Poznan (Poland)</i>	P. Vírtej, <i>Bucharest (Romania)</i>
G. R. Di Paola, <i>Buenos Aires (Argentina)</i>	C. Marth, <i>Innsbruck (Austria)</i>	P.-H. Wang, <i>Taipei (Taiwan)</i>
F. Di Re, <i>Milan (Italy)</i>	Leon F. A. G. Massuger, <i>Nijmegen (The Netherlands)</i>	R. Winter, <i>Graz (Austria)</i>
P. Di Saia, <i>Orange, CA (USA)</i>		Y. Yokoyama, <i>Hirosaki (Japan)</i>
S. K. Fotiou, <i>Athens (Greece)</i>		J. Zielinski, <i>Warsaw (Poland)</i>

*Publisher Organization:*

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc  
Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)  
Tel. +514-4893242-4893640 - Fax +514-4854513 - E-mail: canlux@qc.aira.com  
www.irog.net

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

## General Information

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

### AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

**ANNOUNCEMENTS** regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.

**BOOK SAMPLES** for review should be sent to the Editorial offices in Montréal or in Padova.

**COPYRIGHT:** the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

**ADVERTISING INFORMATION:** advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H3, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@qc.aira.com - www.irog.net

### SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

**Subscriptions are entered with prepayment only.** The annual subscription is \$390 US for Institutions, \$260 US for Individuals and \$120 US for Members of Society of Gynaecological Oncology all over the world. For air mail add \$30. Single copies prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.**

**Claims** for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via Montona 4, Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

# European Journal of Gynaecological Oncology

## Instructions to Authors

### SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storie 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószse, Editor-in-Chief of this section, PO Box 46, 1031 Budapest, Hungary, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@mail.matav.hu.

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

**Publication time will be the shortest possible** based on scientific and publishing needs. **Manuscripts submitted for publication cannot be returned.**

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

### MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three *manuscripts*, typed and double spaced should be submitted **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0**. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which they read and approved, and which has never been published or submitted for publication elsewhere. Name, address and phone/fax numbers of the **Corresponding Author**, responsible for revision and approval of the proofs, should be indicated. Full-length **articles** should not exceed 8 printed pages including tables and references.

After the **title page** (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: **Summary** (*purpose of investigation, methods, results, conclusion - about 150 words*), **Key words, Content** (a 20-word summary), **Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement** (if any), **References, Tables, Legends**.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

**Authors** must give their complete professional identifications and affiliations, including all academic titles and positions.

In general, **no more than six authors is considered appropriate**. Authors' names cannot be changed after submission.

**Letters to the editor** should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

**Figures:** Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

**Legends** should be typed on a separate page with Arabic numerals corresponding to the illustrations.

**Tables** should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

**References should be numbered consecutively in the order in which they are first mentioned in the text.** Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

**Articles in Journals:** Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue, Pages.

**Books:** Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Pages.

**Acknowledgments** will be limited to appropriate professionals who were contributors to the paper.

**PROOFS** revised by the editorial staff will be sent to the corresponding author by the publisher and should be checked and returned within 10 days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered as approved**. Only essential corrections should be made; extensive changes will be charged to the authors.

### BUSINESS MATTERS

The Journal has no commercial advertisements. **Authors will be expected to contribute to the printing expenses, tables, clichés and postage.** For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.**

**Reprints** should be requested with the form enclosed with the acceptance letter.

No free reprints will be supplied. Authors should supply a complete address for reprint requests.

**Individual subscribers** are entitled to publish works, no longer than two printed pages with 25 reprints, free of charge (excluding tables, figures, illustrations, postage), and to have discounts on additional pages and on reprints over the 25 provided free of charge.

# Contents - Volume XXIII, n. 6, 2002

## DISTINGUISHED EXPERT SERIES

- How to improve cytologic screening for endocervical adenocarcinoma?** 481  
M. E. Boon, E. Ouwerkerk-Noordam, A. W. F. M. van Leeuwen, L. P. Kok, C. van Haaften-Day - *Groningen, THE NETHERLANDS*  
The diagnosis of adenocarcinoma of the endocervix in cervical smears can be difficult. The methods for improving this diagnosis in screening programs are considered.

## EDITORIAL ARTICLES

- EUROGIN 2003 Conference. Facts, figures and impact** 487  
J. Monsonego - *Paris, FRANCE*  
The progress in early diagnosis and prevention of cervical cancer in the new millennium are analyzed. The new advances in knowledge about human papillomavirus infections and neoplasia and sexually transmitted infections are stressed.

## ORIGINAL ARTICLES

- Evaluation of the circulating fraction of the HER-2/*neu* oncogene in patients with cervical cancer** 491  
D. N. Contreras, E. Cobos, C. D. Lox - *Lubbock, TX, USA*  
The purpose was to evaluate the circulating fraction of the HER-2/*neu* proto-oncogene in patients with cervical cancer.
- What is the role of interval blood testing in the management of chemotherapy for gynecologic malignancies** 496  
R. J. Cardosi, J. V. Fiorica, E. C. Grendys Jr. - *Tampa, FLORIDA, USA*  
Routine interval blood testing is not always necessary when administering chemotherapy for gynecologic malignancies.
- Does FIGO clinical stage influence the survival of patients with early stages of uterine cervix carcinoma** 501  
M. Martin-Loeches, R. M. Orti, I. Aznar, E. Asins, J. Llixiona - *Valencia, SPAIN*  
Clinical stage influences the prognosis and evolution of patients with early stages of uterine cervix carcinoma, though it is not related to survival intervals.
- Prognostic significance of apoptotic index and bcl-2 and p53 expression in epithelial ovarian carcinoma** 505  
B. Berker, I. Dunder, A. Ensari, S. D. Cengiz, E. Simsek - *Ankara, TURKEY*  
Neither p53 or bcl-2 immunoreactivity nor apoptotic index were found to be of prognostic significance in patients with epithelial carcinomas of the ovary.
- Chlamydia trachomatis* infection in women with CIN and invasive uterine cervix cancer. Significance of hormonal status** 511  
J. Markowska, N. Fischer, Z. Fischer, J. B. Warchol - *Poznan, POLAND*  
Chronic infection with Cht decreases EGFR expression in women with CIN and invasive cancer of the uterine cervix regardless of the hormonal status of the patients. Cht infection remains related to uterine cervix hypertrophy in all groups of women: in the control population, among patients with CIN, and those with invasive cancer.
- Sialyltransferase family members and cervix squamous cell carcinoma** 514  
C. L. Chen, W. L. Lee, Y. C. Tsai, C. C. Yuan, H. T. Ng, P. H. Wang - *Taipei, TAIWAN*  
At least two of the sialyltransferase family members play an important role in cervix squamous cell carcinoma. Enhanced ST6Gal I expression occurs in early-stage cervical cancer and overexpression of ST3Gal III follows when the tumor initiates lymph-node metastases.
- Vulvar lichen sclerosus in postmenopausal women: a comparative study for treating advanced disease with clobetasol propionate 0.05%** 519  
E. S. Diakomanolis, D. Haidopoulos, M. Syndos, A. Rodolakis, K. Stefanidis, J. Chatzipapas, S. Michalas - *Athens, GREECE*  
Severe lesions of vulvar lichen sclerosus in postmenopausal women can be treated with clobetasol propionate 0.05% under close surveillance for a longer time and on a regular basis without adverse side-effects.
- Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis** 523  
M. Rotondi, D. Labriola, M. Rotondi, F. P. Ammaturo, G. Amato, C. Carella, A. Izzo, S. Panariello - *Naples, ITALY*  
Medical treatment of pelvic endometriosis: a comparison of the efficacy and safety of leuprorelin acetate depot and danazol for endometriosis in infertile women.
- Cancer pain, pathophysiology, characteristics and syndromes** 527  
H. Kocoglu, L. Pirbudak, S. Pence, O. Balat - *Gaziantep, TURKEY*  
This paper is a review of the pathophysiology of cancer pain, characteristics of cancer pain, cancer pain syndromes and principles of cancer pain management.
- Gains and losses of CD8, CD20 and CD56 expression in tumor stroma-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and lymphocytes from tumor draining lymph nodes in serous papillary ovarian carcinoma patients** 533  
N. Papadopoulos, A. Kotini, A. Cheva, T. Jivannakis, J. Manavis, G. Alexiadis, M. Lambropoulou, S. Vavet-sis, D. Tamiolakis - *Alexandroupolis, GREECE*  
Depletion of CD8+ (T-cytotoxic) and CD56+ (NK) cells penetrating the serous papillary ovarian tumor stroma may explain the adverse prognosis of the disease.

<b>Cytologic endometrial surveillance in tamoxifen-treated women</b>	537
F. L. Labi, M. L. Meggiorini, M. P. Nusiner, A. Di Lillo, S. L. Casciulli, N. O. Ogbonna, E. V. Cosmi - <i>Rome, ITALY</i> Endometrial modifications tamoxifen-induced can be studied by the endocyte sampler, an economic, simple and painless cytologic device.	
<b>Prognostic significance of DNA Topoisomerase II-<math>\alpha</math> (Ki-S1) immunoeexpression in endometrial carcinoma</b>	540
K. Bildirici, N. Tel, S. S. Ozalp, O. T. Yalcin, V. Yilmaz - <i>Eskisehir, TURKEY</i> DNA Topoisomerase II- $\alpha$ (Ki-S1) immunostaining is an accurate indicator of the biological behavior of endometrial carcinoma.	
<b>Cervical cuff carcinoma: causes and prevention</b>	545
Z. Tsitsishvili, L. Charkviani, T. Charkviani - <i>Tbilisi, GEORGIA</i> The incidence of carcinoma of the cervical cuff in Georgia within the last decade has been increasing. To prevent development of this carcinoma in the future accurate colposcopic examination with target cytology needs to be planned implemented.	
<b>p53 expression in tissue adjacent to endometrial carcinoma</b>	548
E. B. Shem, Y. Fintsi, I. Avinoach, M. Glezerman, J. Menczer - <i>Tel-Aviv, ISRAEL</i> Our findings may indicate that p53 alterations are not necessarily a late event in endometrial endometrioid carcinogenesis.	
<b>Vulvar Paget's disease: review of the literature, considerations about histogenetic hypothesis and surgical approaches</b>	551
A. Tinari, S. Pace, M. Fambrini, D. Eleuteri Serpieri, A. Frega - <i>Rome, ITALY</i> Paget's disease of the vulva is a rare neoplasm that occurs on the apocrine glands. It predominantly is an intraepithelial lesion, but has the potential for dermal invasion and on occasion has been associated with an underlying adenocarcinoma.	
<b>Surgical Stage III endometrial cancer: analysis of treatment outcomes, prognostic factors and failure patterns</b>	553
A. Ayhan, C. Taskiran, C. Celik, K. Yuce, T. Aksu - <i>Ankara, TURKEY</i> In this study the survival estimates, prognostic factors and failure patterns of patients with FIGO stage III endometrial cancer were evaluated.	
<b>Effects of tamoxifen administration in rat vaginas: an ultrastructural and light microscopy study</b>	557
M. A. Ketani, Ş. Ketani, C. Kaloğlu, B. Güney - <i>Sivas, TURKEY</i> We aimed to investigate tamoxifen (TAM) administration on vagina development in rats. Neonatal TAM administration affected the vagina and led to decreasing birth body weight and vaginal adenosis.	
<b>CASE REPORTS</b>	
<b>Abdominal wall metastasis from ovarian cancer after laparotomy. A case report</b>	561
M. A. Baron, J. M. Ladonne, B. Resch - <i>Rouen, FRANCE</i> Extreme caution is recommended when removing a potentially malignant neoplasm during open laparotomy in order to avoid parietal dissemination.	
<b>Endometrial metastasis from signet-ring breast carcinoma: case report</b>	563
A. Chehal, M. Seoud, A. Taher, N. Salem, A. Khalil, A. Shamseddine - <i>Beirut, LEBANON</i> A rare case of signet-ring breast cancer metastatic to the endometrium is presented. The prognostic significance is discussed and the literature reviewed.	
<b>Intraperitoneal haemorrhage secondary to perforation of uterine fibroid after cystic degeneration. Unusual CT findings resembling malignant pelvic tumor: case report</b>	565
M. Varras, S. Antoniou, Ch. Samara, S. Frakala, Z. Angelidou-Manika, P. Paissios - <i>Athens, GREECE</i> Unusual computed tomography manifestations of a myomatous uterus with perforation of a nonpedunculated, subserosal, benign, cystic degenerated fibroid resembling malignant pelvic tumor in described.	
<b>Ultrasonographic and computed tomography manifestations of intussusception secondary to primary non-Hodgkin's lymphoma diagnosed in puerperium: report of a case and review of the literature</b>	569
Ch. Samara, A. Tsikini, S. Antoniou, D. Polyzos, M. Varras - <i>Athens, GREECE</i> A rare case of Stage IV non-Hodgkin's lymphoma diagnosed in puerperium because of intussusception and description of the ultrasonographic and computed tomography manifestations is presented. Also, emphasis is given to the diagnostic dilemmas of non-Hodgkin's lymphoma during pregnancy.	
<b>Primary invasive vaginal cancer. Report of 12 cases</b>	573
E. Diakomanolis, A. Rodolakis, K. Stefanidis, D. Haidopoulos, G. Blachos, J. Kavalakis, S. Michalas - <i>Athens, GREECE</i> Early detection of vaginal cancer could lead to more successful management.	
<b>Vaginal fibroma. Case Report</b>	575
G. J. Daskalakis, C. D. Karabinas, N. E. Papantoniou, I. A. Papaspyrou, A. J. Antsaklis, S. Michalas - <i>Athens, GREECE</i> A case of vaginal fibroma is reported and the management and the differential diagnosis is discussed.	
<b>Primary small-cell carcinoma of the endometrium: Clinicopathological study of a case and review of the literature</b>	577
M. Varras, Ch. Akrivis, A. Demou, G. Hadjopoulos, S. Stefanaki, N. Antoniou - <i>Ioannina, GREECE</i> An extremely rare case of primary small-cell carcinoma of the endometrium is presented and the clinical, histological and immunohistochemical features are discussed.	
Contents index vol. XXIII, 2002	582
Authors index vol. XXIII, 2002	590

## Index of Authors in alphabetical order

- Ackerman I., 187  
Adam S. M., 472  
Aduana V. A., 279  
Agnantiss N. J., 320, 341  
Akdeniz N., 460  
Akdeniz S., 460  
Akercan F., 257  
Akhan S. E., 330  
Akkuş Z., 79  
Akrivis Ch., 227, 577  
Akrivos T., 139  
Aksoy F., 84  
Aksu T., 553  
Alderisio M., 211  
Alexiadis G., 533  
Alò P. L., 45  
Altuglu I., 166  
Amaral N., 191  
Amato G., 523  
Ambrosini G., 154, 163  
Ammaturo F. P., 523  
Ampil F. L., 291  
Angelidou-Manika Z., 353, 565  
Antoniadis Th., 475  
Antoniou N., 227, 577  
Antoniou S., 353, 565, 569  
Antonopoulou Z., 333  
Antsklis A. J., 575  
Argyrou K., 139  
Arican A., 58  
Arslan A., 72  
Asins E., 501  
Aubard Y., 37  
Aube J., 187  
Aurello P., 442  
Avinoach I., 548  
Aydm A., 84  
Ayhan A., 451, 553  
Aznar I., 501  
Azzena A., 317
- Baekelandt M., 383  
Baigal G., 397  
Bal C., 243  
Balat Ö., 472  
Balat O., 84, 366, 378, 437, 527  
Balbi C., 347  
Balbi G., 347  
Bálega J., 415  
Barbetakis N., 475  
Baron M. A., 561  
Bartos P., 305  
Bayhan G., 79  
Bayjak Y., 451  
Baykal C., 451  
Bekkers R. L. M., 203  
Benedet J. L., 5  
Bengisu E., 330  
Berisavac M., 42  
Berker B., 505
- Berkman S., 330  
Bertezzo M., 317  
Beshara N., 287  
Bildirici K., 540  
Bilgiç A., 166  
Biran G., 157  
Blachos G., 573  
Bobos M., 411, 453  
Boon M. E., 481  
Boonstra H., 203  
Borrvalho R., 191  
Bozkurt S. U., 261  
Branca M., 211  
Bukovsky I., 300  
Bulten J., 203  
Busby G., 68  
Büyükerberber N., 472  
Büyükerberber S., 472
- Cabero-Roura L., 5  
Caldito G., 291  
Calpaktsoylou C., 463  
Camci C., 437, 472  
Can I., 50  
Canetto A. M., 154  
Capobianco G., 154, 163  
Cararach M., 269  
Cardone A., 347  
Cardosi R. J., 496  
Carella C., 523  
Carey M., 187  
Carvalho F. Marino, 11  
Casciulli S. L., 537  
Cassese E., 347  
Castaigne D., 293  
Cavina R., 115  
Celik C., 553  
Çelik Ö. K., 58  
Cengiz S. D., 505  
Cerrotta A., 115  
Chang C. T., 178  
Chao H. T., 131  
Chao K. C., 35  
Charkviani L., 545  
Charkviani T., 545  
Chatzipapas J., 519  
Chatzipappas I., 457  
Chehal A., 563  
Chen A. C. Y., 401  
Chen C. L., 514  
Chen D. P., 63  
Chen Y. J., 131  
Cherchi P. L., 154, 163  
Cheva A., 411, 433, 453, 469, 533  
Chew S. H., 251  
Chiarelli S., 317  
Chiarini F., 45  
Chiu L. M., 17  
Chouliara S., 341  
Cicchini C., 442  
Ciglar S., 133  
Cinel L., 345  
Cintorino M., 145  
Clavère P., 37  
Cobos E., 491  
Contreras D. N., 491  
Cosio S., 295, 390
- Cosmi E. V., 537  
Cristofani R., 295  
Csabay L., 29  
Csapó Zs., 29, 74, 207, 415
- Daskalakis G. J., 575  
Davidson E. J., 320  
De Loecker P. A. J., 423  
De Marzi P., 216  
de Oliveira C. F., 191  
De Palo G., 115  
Deavers M. T., 199  
Dede M., 426  
Degener A. M., 45  
Deligiannis D., 475  
Demeter A., 207, 415  
Demiroglu A., 451  
Demou A., 577  
Dertimas B., 139  
Dessole S., 154, 163  
Deveci E., 50  
Dexeus D., 269  
Dexeus S., 269  
Di Bonito L., 211  
Di Lillo A., 537  
Di Prisco L., 347  
Diakomanolis E., 447, 457, 463, 573  
Diakomanolis E. S., 519  
Dikmen Y., 257, 264  
Dimopoulou C., 70  
Distant G., 445  
Dögan R., 451  
Doong J. L., 401  
Douglas G., 211  
Doun J. L., 199  
Dousias V., 341  
Doussias V., 320  
Duić Ž., 133  
Dundar E., 243, 419  
Dunder I., 505
- Eim J., 305  
Eisenhauer E. A., 104  
Ekicioğlu G., 261  
Eleuteri Serpieri D., 551  
Elit L., 104, 187, 397  
Elsheikh A., 447  
Englezou M., 70  
Ensari E., 505  
Eralp A., 50  
Erhan Y., 264  
Erkılıç S., 84  
Esassolak M., 58  
Esinler I., 451  
Etiz E., 337  
Eyraud J. L., 37
- Fabrizi G., 323  
Fadda G. M., 154, 163  
Fambrini M., 551  
Farantos Ch., 353  
Fattorini F., 163  
Faught W., 287  
Ferreri R., 445  
Ferrero A. M., 236, 295  
Ficorella C., 335
- Fintsi Y., 548  
Fiorica J. V., 496  
Fischer N., 247, 511  
Fischer Z., 511  
Frakala S., 565  
Frangou-Plemenou M., 70  
Frega A., 551  
Frigerio L., 216  
Fukasawa H., 183  
Fulciniti F., 211  
Füle T., 74  
Fung Kee Fung M., 104, 287  
Fuso L., 236  
Fyles A., 187
- Gadducci A., 295, 390  
Galanis P., 227  
Gallai M., 74  
Garancini P., 216  
Garassino I., 115  
Gardani G., 115  
Gemer O., 21  
Genazzani A. R., 390  
Genet D., 37  
Giovagnoli M. R., 45, 211  
Glezerman M., 157, 548  
Gózdzička-Józefiak A., 231, 311  
Gogas H., 333  
Gogas J., 333  
Gökmen O., 345  
Göksu S., 366  
Golan A., 157  
Gomes C., 191  
Goshen R., 187  
Grendys Jr. E. C., 496  
Güney B., 557
- Hadas E., 300  
Hadjopoulos G., 577  
Haidopoulos D., 447, 457, 463, 519, 573  
Halperin R., 300  
Hanselaar A. G. J. M., 203  
Haydaroglu A., 58  
Hirata S., 183  
Hirsch P. M., 320  
Hirte H. W., 104  
Ho T. H., 251  
Holub Z., 53, 305  
Honda T., 183  
Hoshi K., 183  
Hsu C. C., 221  
Hücumenoğlu S., 261
- Ietta F., 145  
İnalöz H. S., 50  
İnalöz S. S., 50  
İndinnimeo M., 442  
İşikoglu M., 330  
Isıksoy S., 243  
Ivanov S., 161  
Izzo A., 523  
Iwamoto H., 183

- Jabor A., 53, 305  
 Jack E., 397  
 Jacomuzzi M., 236  
 Jernström H., 187  
 Jivannakis T., 411, 433, 453, 469, 533  
 Johnston M. E., 104  
 Jovanovic T., 42  
 Juang C. M., 17, 131
- Kabukcuoglu S., 243, 337  
 Kaern J., 383  
 Kairi-Vassilatou E., 70  
 Kalantaridou S. N., 341  
 Kaloğlu C., 557  
 Kaplanis K., 475  
 Kaponis A., 341  
 Karabinas C. D., 575  
 Karseladze A. I., 173  
 Kaspar H. G., 429  
 Kassanos D., 358  
 Katis K., 353  
 Katsoulis M., 139  
 Kavalakis J., 573  
 Kaya H., 261  
 Kazandi A. C., 264  
 Kazandi M., 257, 264  
 Ketani M. A., 557  
 Ketani Ş., 557  
 Khalil A., 563  
 Khi C., 251  
 Kilic G., 279  
 Kiliç N., 72  
 Kimura N., 183  
 Kioses E., 327  
 Kliment L., 53  
 Kocoglu H., 366, 527  
 Kok L. P., 481  
 Koliopoulos G., 113, 320, 363  
 Kondi-Pafiti A., 70  
 Kontzoglou K., 333  
 Korbowicz E., 311  
 Kostopanagiotou E., 353  
 Kotiloğlu E., 261  
 Kotini A., 411, 433, 453, 469, 533  
 Kouskos E., 333  
 Kovalszky I., 74  
 Kukura V., 133  
 Kuljic-Kapulica N., 42  
 Kuruvilla A., 68  
 Kutlar I., 84  
 Kwaśniewska A., 231, 311
- Labi F. L., 537  
 Labriola D., 523  
 Ladonne J. M., 561  
 Lai C. R., 35  
 Lamaina V., 123  
 Lambropoulou M., 411, 433, 453, 469, 533  
 Landoni F., 295  
 Langer R., 300  
 Lanza P., 151  
 Larcinese A., 442  
 Lauri F., 151
- Lee T. W., 178  
 Lee W. L., 221, 514  
 Leron E., 120  
 Lin T. W., 221  
 Lippert C., 127  
 Lissoni A., 295  
 Litta P., 151  
 Llixiona J., 501  
 Lo W. L., 221  
 Loizzi P., 445  
 Loizzi V., 445  
 Lolis D. E., 341  
 Lolis E., 320  
 Lopez L. I., 323  
 Low J. J. H., 251  
 Lox C. D., 491  
 Lukic A., 45
- MacLean A. B., 111  
 Maggino T., 295  
 Magistris A., 236  
 Mahji U., 135  
 Malamou-Mitsi V., 320  
 Malpica A., 199  
 Manavis J., 533  
 Mangili G., 216  
 Mantas D., 333  
 Marchetti M., 123, 151  
 Marchetti P., 335  
 Marchioro S., 123  
 Markopoulos C., 333  
 Markowska J., 511  
 Marques C., 191  
 Martin-Hirsch P. L., 363  
 Martin-Loeches M., 501  
 Massi G., 323  
 Massuger L. F. A. G., 203  
 Matsui H., 281  
 Mazor M., 120  
 Mazzola S., 236  
 Meggiorini M. L., 537  
 Melchers W. J. G., 203  
 Menczer J., 157, 548  
 Menditto A., 347  
 Messaris E., 463  
 Michailidis E., 358  
 Michalás S., 457, 463, 519, 573, 575  
 Migliore G., 211  
 Miliaras D., 350  
 Milingos S., 447  
 Mingazzini P. L., 442  
 Mitchell M., 187  
 Miturski R., 231  
 Monsonego J., 487  
 Montanari G., 211  
 Moretti D., 211  
 Morice P., 293  
 Morosini P., 211  
 Moszynski R., 325  
 Mroueh A. M., 429  
 Mudu P., 211  
 Mueck A. O., 127  
 Munkhtaivan A., 397  
 Muraca S., 390  
 Musone R., 347  
 Musumeci R., 115
- Nabaei S. B., 345  
 Nagai Y., 281  
 Narducci F., 335  
 Narod S. A., 187, 397  
 Navone R., 211  
 Nesland J. M., 93  
 Ng H. T., 17, 178, 514  
 Nieto J. J., 111  
 Nobili F., 45  
 Nusiner M. P., 537
- Obgonna N. O., 537  
 Oğuz S., 345  
 Oner U., 366  
 Onnis A., 4, 373  
 Opala T., 325  
 Orti R. M., 501  
 Ouwerkerk-Noordam E., 481  
 Ozacar T., 166  
 Ozalp S. S., 243, 337, 361, 419, 540  
 Ozsaran A. A., 166, 264  
 Ozsaran A., 257  
 Özsaran Z., 58
- Pace S., 551  
 Paissios P., 565  
 Pak Y., 426  
 Pal T., 187  
 Paleogianni V., 139  
 Panagiotopoulos N., 358  
 Panariello S., 523  
 Papadopoulos N., 411, 433, 453, 469, 533  
 Papantoniou N. E., 575  
 Papaspyrou I. A., 575  
 Papp Z., 29, 207, 415  
 Pappa L., 320  
 Paraskevaidis E., 113, 320, 341, 363  
 Paris I., 335  
 Parker L. P., 199  
 Parkin D., 113  
 Paschopoulos M., 320, 341  
 Paulesu L., 145  
 Pautier P., 293  
 Pence S., 527  
 Perovic M., 42  
 Perrett C. W., 111  
 Pete I., 74  
 Philippe H. J., 37  
 Piga M. D., 154, 163  
 Pinotti J. Aristodemo, 11  
 Pirdudak L., 366, 527  
 Piura B., 21, 120, 195  
 Pivovarniková R., 305  
 Podgajski M., 133  
 Podobnik M., 133  
 Polyzos D., 569  
 Porzio G., 335  
 Postawski K., 231  
 Pozzan C., 151
- Quint W. G. V., 203
- Rabaiotti E., 216  
 Rabinovich A., 21, 120, 195  
 Rajkumar T., 135  
 Rakar S., 405  
 Ramsewak S., 68  
 Raspagliesi F., 115  
 Reid W. M. N., 111  
 Renard F., 25  
 Resch B., 561  
 Ricci F., 442  
 Ricci M. G., 145  
 Ricevuto E., 335  
 Rodolakis A., 447, 457, 463, 519, 573  
 Rolfe K. J., 111  
 Romagnoli R., 145  
 Rosen B., 104  
 Rotondi M., 523  
 Rubattu G., 154  
 Ruii G., 163
- Sabatini R., 445  
 Sagiv R., 157  
 Sajdak S., 325  
 Sakellaropoulos G., 463  
 Salamalekis E., 358  
 Salem N., 563  
 Salihoglu Y., 330  
 Samara Ch., 565, 569  
 Sartori E., 295  
 Sassi I., 216  
 Scagnol I., 25  
 Scheistrøen M., 93  
 Schneider D., 300  
 Seeger H., 127  
 Seki K., 281  
 Sekiya S., 281  
 Selvaluxmi G., 135  
 Semczuk-Sikora A., 311  
 Sendag F., 257  
 Seoud M., 563  
 Seoud M. A. F., 429  
 Shamseddine A., 563  
 Shem E. B., 548  
 Sheu M. H., 401  
 Shyong W. Y., 178  
 Signore M., 45  
 Silva E. G., 199  
 Simopoulos C., 433, 469  
 Simsek E., 505  
 Sindos M., 457  
 Sinistrero G., 236  
 Sipsos N., 415  
 Sirikçi A., 84  
 Siristatidis Ch., 358  
 Sismondi P., 236  
 Sotiropoulou M., 447  
 Spadaro M., 123  
 Spanu P., 236  
 Stamatopoulos P., 341  
 Stefanaki S., 227, 577  
 Stefanidis K., 457, 519, 573  
 Stefanon B., 115  
 Stelmachów J., 375  
 Stylianidou A., 227  
 Sung W. H., 401  
 Suzuka K., 281  
 Syciotis C., 358

Sykiotis K., 70  
 Syndos M., 519  
 Szabó I., 29  
 Szánthó A., 29, 74, 207, 415  
 Sziller I., 207  
 Szirmai K., 29, 74  
  
 Taccagni G. L., 216  
 Taher A., 563  
 Tamiolakis D., 411, 433, 453, 469, 533  
 Tana S., 115  
 Tanaka N., 281  
 Taner D., 345  
 Tanir H. M., 361, 419  
 Tanir M., 337  
 Tarakçıoğlu M., 472  
 Tasi Y. C., 221  
 Taskiran C., 553  
 Tasskiran Ç., 451  
 Tay E. H., 251  
 Tel N., 243, 540  
 Terek M. C., 166, 257, 264  
 Tinari A., 551  
 Tisi G., 295  
 Tjalma W. A. A., 423  
  
 Toliou Th., 475  
 Tou N. F., 35  
 Tripodi S. A., 145  
 Tropé C., 93  
 Tropé C. G., 383  
 Tsai L. C., 17, 178  
 Tsai Y. C., 514  
 Tsiaousi J., 139  
 Tsikini A., 569  
 Tsilikas Ch., 475  
 Tsitsishvili Z., 545  
 Tubiana-Mathieu N., 37  
 Tukendorf A., 311  
 Tunca J., 279  
 Türk H. M., 472  
  
 Ulutin H. C., 426  
 Ůnal B., 50  
 Urbánek Š., 305  
 Uršič Vrsčaj M., 405  
 Uzunlar A. K., 72, 79  
  
 van Haaften-Day C., 481  
 van Leeuwen A. W. F. M., 481  
 Van Marck E. A. E., 423  
  
 Vanel D., 293  
 Varras M., 227, 327, 353, 565, 569, 577  
 Vavetsis S., 411, 453, 533  
 Verhest A., 25  
 Versleger I. O. J., 423  
 Vetrano G., 45  
 Viala J., 293  
 Viganò R., 216  
 Vijayalakshmi N., 135  
 Vitali A., 211  
 Vitoratos N., 358  
 Vlahos G., 447  
 Vorgias G., 139  
 Vosse M., 25  
 Voulgaris Z., 447  
  
 Wallwiener D., 127  
 Wang P. H., 17, 131, 178, 221, 401, 514  
 Wharchol J. B., 511  
 Wharton J. T., 199  
 Wu C. Y., 221  
  
 Xiao Y. H., 63  
  
 Yalcin O. T., 337, 361, 419, 540  
 Yaldiz M., 460  
 Yalman D., 58  
 Yan J. H., 63  
 Yanai-Inbar I., 21, 120, 195  
 Yen M. S., 35, 131  
 Yildirim S., 419  
 Yilmaz F., 72, 79  
 Yilmaz V., 540  
 Yokoyama Y., 63  
 Yu B. K. J., 35  
 Yuan C. C., 17, 35, 131, 178, 221, 401, 514  
 Yuce K., 553  
 Yükses M. S., 366  
 Yürüt V., 58  
  
 Zalloua P. A., 429  
 Zambon A., 123  
 Zannol M., 317  
 Zannoni G. F., 323  
 Zehavi S., 300  
 Zen T., 317  
 Zikopoulos K., 320, 341  
 Zola P., 236, 295